Last reviewed · How we verify

Wahba bakhet — Portfolio Competitive Intelligence Brief

Wahba bakhet pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Lidocaine 1%/Epi 1:200000 Lidocaine 1%/Epi 1:200000 marketed Local anesthetic with vasoconstrictor Voltage-gated sodium channels Anesthesia/Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ankara Yildirim Beyazıt University · 1 shared drug class
  2. Health Sciences North Research Institute · 1 shared drug class
  3. Ohio State University · 1 shared drug class
  4. Pontificia Universidad Catolica de Chile · 1 shared drug class
  5. University Hospital, Antwerp · 1 shared drug class
  6. University of Wisconsin, Madison · 1 shared drug class
  7. Vrije Universiteit Brussel · 1 shared drug class
  8. Weill Medical College of Cornell University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Wahba bakhet:

Cite this brief

Drug Landscape (2026). Wahba bakhet — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wahba-bakhet. Accessed 2026-05-16.

Related